Year: 2023

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, our oral PD-L1 checkpoint inhibitor Reducing workforce by 24% as a result of recent pipeline optimization Cash runway extended into first quarter 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today...

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 HighlightsThird quarter 2023 revenue of $17.9 million, an increase of 8% over the third quarter of 2022 Record U.S. treatment session revenue of $13.1 million Shipped 43 NeuroStar systemsRecent Operational HighlightsLaunched the “Better Me Guarantee” Provider pilot program Accessed $22.5 million from existing debt facilityRecent Marketing HighlightsAchieved milestone of over 162,500 global patients treated with...

BRENTWOOD, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading operator of surgical facilities, today announced financial results for the third quarter ended September 30, 2023.Revenues were $674.1 million representing 8.6% growthDays Adjusted Same-facility revenues increased 14.2%Net loss attributable to Surgery Partners was $4.9 millionAdjusted EBITDA was $105.5 million, representing 9.7% growth Adjusted EBITDA margin improved year-over-year to 15.7%Equity earnings in unconsolidated affiliates increased 45.8% to $3.5 millionRevenues from facilities not consolidated increased by 71.2% to $159.6 million Adjusted EBITDA contribution from unconsolidated affiliates was $10.2 million, 29.1% higher than 2022Full year...

Record Third Quarter Revenue, Operating Profit and Operating Profit MarginIncreased Full-Year Free Cash Flow Guidance to Top Half of Range – $350M – $375MAMS and DRS Revenue Exceeds 20% of Total Trailing Twelve-Month Revenue Year-to-Date Net Cash from Operations up 46% and Free Cash Flow up 197% Results Highlights:Q3 Revenue up 8%, reflecting 6% organic growth Q3 Operating profit: GAAP up 131% to $138M; non-GAAP up 31% to $166M Q3 Operating profit margin: GAAP up 115% to 11.2%; non-GAAP up 21% to 13.5% Q3 GAAP net income up 138% to $46M; adjusted EBITDA up 22% to $231M Q3 EPS: GAAP $0.97; non-GAAP $1.92 YTD GAAP net cash from operations up $93M to $293M; free cash flow up $143M to $216MRICHMOND, Va., Nov. 07, 2023 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables...

BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023.    The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia, in advance of the February 26, 2024 PDUFA date. “We remain committed to bringing roluperidone to patients and physicians as we believe it addresses a significant unmet clinical need and has the potential to improve patients’ quality of life and expand treatment options available to physicians. If approved,...

– SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported – – Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new clinical data milestones anticipated throughout 2024 – – Strong balance sheet with cash runway into the second half of 2025 – BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates. “The third quarter of 2023 was marked by significant progress,...

Revenue Grew to $60.3 Million Driven by Recurring Revenue Growth of 48% YoY Net Income (Loss) Improved by almost $7 Million Compared to Q3 2022 Reaffirms FY 2023 Revenue Outlook and YoY Growth of at Least 35% Raises Lower End of FY 2023 Earnings Guidance Range HERZLIYA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq, TASE: NYAX), a global commerce enablement, payments and loyalty platform designed to enable retailers to provide consumers with digital, cashless, connected commerce experiences, and enhance consumer loyalty and conversion, today announced its financial results for the third quarter 2023. “Our strong third quarter performance was highlighted by a 48% increase in recurring revenue and overall gross margin, which continued trending higher to 38%, mostly driven by ongoing hardware gross margin improvement....

MANITOWOC, Wis., Nov. 07, 2023 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, maintenance services and electric vehicle (EV) charging station solutions, today reported results for its fiscal 2024 second quarter (Q2’24) ended September 30, 2023. Orion will hold an investor call today at 10:00 a.m. ET – details below.Q2 Financial Summary   Prior Three Quarters$ in millions except per share figures Q2’24 Q2’23 Change   Q1’24 Q4’23 Q3’23Revenue $20.6 $17.6 $3.0   $17.6 $21.6 $20.3Gross Profit $4.6 $4.4 $0.1   $3.2 $4.7 $4.8Gross Profit % 22.2% 25.3% (306 bps)   18.0% 21.9% 23.6%Net Loss (1) ($4.4) ($2.3) ($2.1)   ($6.6) ($5.1) ($24.1)Net Loss per share (1) ($0.14) ($0.07) ($0.07)   ($0.21) ($0.16) ($0.75)Adjusted EBITDA (2) ($2.2) ($1.5) ($0.7)   ($4.4) ($1.6) ($1.6)Cash...

Revenues Grew 6% to $63.9 million;GAAP Operating Income of $12.7 million and Adjusted EBITDA of $9.5 million, 30% Growth Year-over-Year; PETAH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, reported today its results for the third quarter, ended September 30, 2023. Third Quarter 2023 Financial HighlightsRevenues of $63.9 million, up 6% compared with $60.4 million in Q3 2022; GAAP operating income of $12.7 million compared with $3.4 million in Q3 2022;GAAP operating income in this quarter includes a one-time other income, net, of $7.4 million, that was recorded with respect to a settlement of legal proceedings in the Philippines and a real estate sale in Bulgaria; Non-GAAP operating income of...

~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in refractory mesial temporal lobe epilepsy ~ ~ On track to provide clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease later in the fourth quarter of 2023 ~ ~ uniQure and CSL win 2023 Prix Galien USA award for HEMGENIX® ~ ~ Announced strategic reorganization to focus on advancing multiple clinical-stage programs and expect to deliver $180 million of cost savings over the next three years ~ ~ Strong cash position of approximately $660 million as of September 30, 2023 expected to fund operations into the second quarter of 2027 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 07, 2023 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...